Provided are an organic salt represented by Formula 1, a photoresist composition including the same, and a pattern method using the same:

##STR00001##

wherein X.sup.+, Y.sup.?, and R.sub.11 to R.sub.13 in Formula 1 are understood by referring to the specification.

Provided are an organic salt represented by Formula 1, a photoresist composition including the same, and a pattern method using the same:

##STR00001##

wherein X.sup.+, Y.sup.?, and R.sub.11 to R.sub.13 in Formula 1 are understood by referring to the specification.

Provided herein are free base crystalline forms, crystalline salts, and an amorphous salts of omecamtiv mecarbil.

The invention relates to new 1:1 olaparib:hydroxybenzoic acid cocrystals. The invention also relates to new 2:1 olaparib:hydroxybenzoic acid cocrystals which may contain no water (anhydrous) or may optionally be hydrated. The invention also relates to pharmaceutical compositions containing an olaparib hydroxybenzoic acid cocrystal of the invention and a pharmaceutically acceptable carrier. The olaparib hydroxybenzoic acid cocrystals of the invention may be useful for the treatment of diseases that benefit from inhibition of poly (ADP-ribose) polymerase (PARP).

The invention relates to new 1:1 olaparib:hydroxybenzoic acid cocrystals. The invention also relates to new 2:1 olaparib:hydroxybenzoic acid cocrystals which may contain no water (anhydrous) or may optionally be hydrated. The invention also relates to pharmaceutical compositions containing an olaparib hydroxybenzoic acid cocrystal of the invention and a pharmaceutically acceptable carrier. The olaparib hydroxybenzoic acid cocrystals of the invention may be useful for the treatment of diseases that benefit from inhibition of poly (ADP-ribose) polymerase (PARP).

This invention relates to a process for preparing an alkylsalicylic acid. The process comprises reacting salicylic acid with an olefin having at least four carbon atoms at a temperature ranging from about 50 C. to about 200 C. in the presence of an arylsulfonic acid-containing catalyst (such as para-toluene sulfonic acid), to produce an alkylsalicylic acid. The resulting alkylsalicylic acid has various applications such as a food preservative, an oil field chemical for oil recovery, and a component in a color toner agent for electrophotography.

This invention relates to a process for preparing an alkylsalicylic acid. The process comprises reacting salicylic acid with an olefin having at least four carbon atoms at a temperature ranging from about 50 C. to about 200 C. in the presence of an arylsulfonic acid-containing catalyst (such as para-toluene sulfonic acid), to produce an alkylsalicylic acid. The resulting alkylsalicylic acid has various applications such as a food preservative, an oil field chemical for oil recovery, and a component in a color toner agent for electrophotography.

New tranilast complexes and new tranilast cocrystals are disclosed. These include a 1:1 tranilast nicotinamide complex, a 1:1 tranilast nicotinamide cocrystal, a 1:1 tranilast saccharin complex, a 1:1 tranilast saccharin cocrystal, a 1:1 tranilast gentisic acid complex, a 1:1 tranilast gentisic acid cocrystal, a 1:1 tranilast salicylic acid complex, a 1:1 tranilast salicylic acid cocrystal, a 1:1 tranilast urea complex, a 1:1 tranilast urea cocrystal, a 1:1 tranilast 4-aminobenzoic acid complex, a 1:1 tranilast 4-aminobenzoic acid cocrystal, a 1:1 tranilast 2,4-dihydroxybenzoic acid complex and a 1:1 tranilast 2,4-dihydroxybenzoic acid cocrystal. Also disclosed are pharmaceutical compositions containing a tranilast complex or cocrystal of the invention and a pharmaceutically acceptable carrier. Methods of treatment using the tranilast complexes and cocrystals as well as the pharmaceutical compositions are disclosed.

New tranilast complexes and new tranilast cocrystals are disclosed. These include a 1:1 tranilast nicotinamide complex, a 1:1 tranilast nicotinamide cocrystal, a 1:1 tranilast saccharin complex, a 1:1 tranilast saccharin cocrystal, a 1:1 tranilast gentisic acid complex, a 1:1 tranilast gentisic acid cocrystal, a 1:1 tranilast salicylic acid complex, a 1:1 tranilast salicylic acid cocrystal, a 1:1 tranilast urea complex, a 1:1 tranilast urea cocrystal, a 1:1 tranilast 4-aminobenzoic acid complex, a 1:1 tranilast 4-aminobenzoic acid cocrystal, a 1:1 tranilast 2,4-dihydroxybenzoic acid complex and a 1:1 tranilast 2,4-dihydroxybenzoic acid cocrystal. Also disclosed are pharmaceutical compositions containing a tranilast complex or cocrystal of the invention and a pharmaceutically acceptable carrier. Methods of treatment using the tranilast complexes and cocrystals as well as the pharmaceutical compositions are disclosed.

A multi-branched cationic phosphonium salt is provided. The multi-branched cationic phosphonium salt has a structure represented by formula (I):

{Z[P.sup.+(R.sup.1)(R.sup.2)(R.sup.3)].sub.n}(X.sup.).sub.n(I) wherein each of R.sup.1, R.sup.2, and R.sup.3 is independently a linear or branched C.sub.1C.sub.10 alkyl group, X.sup. is an organic or inorganic anion, and Z has a structure represented by Formula (IIb) or Formula (IIc):

##STR00001## wherein a is an integer of 115. In Formulas (IIb) and (IIc), Z is connected to [P.sup.+(R.sup.1)(R.sup.2)(R.sup.3)] at the position marked by an asterisk (*), and n is an integer of 34.